Alvin J. Siteman Cancer Center

Last updated
Alvin J. Siteman
Cancer Center
Alvin J. Siteman Cancer Center
Geography
Location St. Louis, Missouri, United States
Organization
Type Specialist
Affiliated university Barnes-Jewish Hospital, Washington University School of Medicine
Services
Speciality Cancer
Public transit access Bus-logo.svg MetroBus
BSicon TRAM.svg   Red    Blue  
At Central West End station
History
Opened1999
Links
Website www.siteman.wustl.edu
Lists Hospitals in Missouri

The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is a cancer treatment, research and education institution with six locations in the St. Louis area. Siteman is the only cancer center in Missouri and within 240 miles of St. Louis to be designated a Comprehensive Cancer Center by the National Cancer Institute (NCI). [1] Siteman is also the only area member of the National Comprehensive Cancer Network, [2] a nonprofit alliance of 32 cancer centers dedicated to improving the quality and effectiveness of cancer care. [3]

Contents

Siteman treats more than 75,000 individual patients, including 12,000 newly diagnosed patients, every year. [4]

Locations

Siteman's main facility is at Washington University Medical Center in St. Louis’ Central West End neighborhood. In 2021, work began on a new main facility on the medical campus that is scheduled for completion in summer 2024. [5] Five other St. Louis-area sites offer specialized cancer care in suburban locations:

History and leadership

In 1999, Alvin J. and Ruth Siteman committed $35 million to the development of the Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital. The commitment was the largest gift ever received by Barnes-Jewish and Washington University in support of cancer research, patient care and services, education and community outreach. [9]

Timothy Eberlein has been director of the center since its inception. [10] John DiPersio is deputy director. [11]

In 2001, the NCI designated Siteman as a Cancer Center, which signaled that the institution had demonstrated significant scope and quality in its cancer research programs. The designation came with $850,000 per year in federal research grants. [12] The NCI named Siteman a Comprehensive Cancer Center in 2005, recognizing its broad-based research, outreach and education activities, and awarded the center a five-year, $21 million support grant. [13] The NCI renewed the designation in 2010 and awarded another five-year grant, totaling $23 million. The grants fund programs and specialized services that promote multidisciplinary research, as well as shared scientific resources and seed awards that enable investigators to develop and pursue new research opportunities. [14]

Alvin J. Siteman announced in 2010 that he would donate $1 million annually to an endowment fund at the center to advance cancer prevention, diagnosis and treatment programs that might not receive federal funding. [15]

Patient care and services

More than 350 Washington University research scientists and physicians provide inpatient and outpatient care at Siteman. [16] The center also offers patient and family support services, including discussion and education groups. [17]

In 2018, Siteman announced it would build a second proton therapy unit at its S. Lee Kling Proton Therapy Center. The first opened in late 2013. [18]

Research

Scientists and physicians affiliated with Siteman hold more than $145 million in cancer research and related training grants. The results of basic laboratory research are rapidly incorporated into treatment advances. This process is enhanced by patient access to more than 500 therapeutic clinical studies, [19] including many collaborative efforts with other leading cancer centers throughout the country. [20]

In 2013, three scientists affiliated with Siteman, Washington University School of Medicine and the McDonnell Genome Institute were included on the Thomson Reuters list of “Hottest Scientific Researchers of 2012”: Richard K. Wilson, Elaine Mardis, and Li Ding. The list recognized the 21 most-cited researchers of 2012. Robert Fulton, a fourth scientist from Washington University School of Medicine and the McDonnell Genome Institute, also made the list. [21]

Research advances

Researchers affiliated with Siteman and/or Washington University School of Medicine have pioneered important advances in cancer research, prevention, education and treatment. Highlights and ongoing studies include these projects:

2018 — Personalized brain cancer vaccines

2017 — CAR-T cell therapy and using Zika virus to fight brain cancer

2016 — Chemotherapy for brain tumors

2015 — Melanoma vaccine and urine test for kidney cancer

2014 — Breast cancer vaccine and cancer goggles

2013 — Endometrial cancer and leukemia

2012 — Leukemia, breast cancer research and cancer prevention

2011 — Blood-related cancers

2010 — Pediatric cancers

2008 — Genetic sequencing

2007 — Nanotechnology and radiation therapy

2006 — Photoacoustic imaging

2003 — Breast cancer

2001 — Imaging and the immune system's role in controlling cancer

1998 — Biopsies

1994 — Genetic screening test for thyroid cancer

1979 — Bone marrow transplants

Mid-1970s — Imaging

1954 — Growth factors and cancer

1946 — Radiocarbon in cancer research

1941 — Cyclotron

1933 — Lung cancer surgery and the disease's link to smoking

Cancer prevention and control

Siteman and Washington University School of Medicine are actively engaged in many projects to prevent cancer in the St. Louis region and across the United States. These efforts include:

Education and community outreach

In addition to treatment and research programs, Siteman is involved with community outreach, education and screening. Efforts include:

Siteman Cancer Network

In 2017, Siteman Cancer Center launched the Siteman Cancer Network, an affiliation with regional medical centers that is aimed at improving the health of individuals and communities through cancer research, treatment and prevention. Network members are Boone Hospital Center's Stewart Cancer Center in Columbia, Missouri, [69] Phelps Health's Delbert Day Cancer Institute in Rolla, Missouri, [70] Alton Memorial Hospital in Alton, Illinois [71] and Southern Illinois Healthcare in Carbondale, Illinois. [72]

Related Research Articles

<span class="mw-page-title-main">Gene therapy</span> Medical technology

Gene therapy is a medical technology that aims to produce a therapeutic effect through the manipulation of gene expression or through altering the biological properties of living cells.

<span class="mw-page-title-main">Cancer</span> Group of diseases involving cell growth

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal bleeding, prolonged cough, unexplained weight loss, and a change in bowel movements. While these symptoms may indicate cancer, they can also have other causes. Over 100 types of cancers affect humans.

This is a list of terms related to oncology. The original source for this list was the US National Cancer Institute's public domain Dictionary of Cancer Terms.

<span class="mw-page-title-main">Roswell Park Comprehensive Cancer Center</span> Hospital in New York, United States of America

Roswell Park Comprehensive Cancer Center is a cancer research and treatment center located in Buffalo, New York. Founded by surgeon Roswell Park in 1898, the center was the first in the United States to specifically focus on cancer research. The center is usually called Roswell Park in short. The center, which conducts clinical research on cancer as well as the development new drugs, provides advanced treatment for all forms of adult and pediatric cancer, and serves as a member of the National Comprehensive Cancer Network. Roswell Park Comprehensive Cancer Center is as of 2019, the only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center".

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.

Virotherapy is a treatment using biotechnology to convert viruses into therapeutic agents by reprogramming viruses to treat diseases. There are three main branches of virotherapy: anti-cancer oncolytic viruses, viral vectors for gene therapy and viral immunotherapy. These branches use three different types of treatment methods: gene overexpression, gene knockout, and suicide gene delivery. Gene overexpression adds genetic sequences that compensate for low to zero levels of needed gene expression. Gene knockout uses RNA methods to silence or reduce expression of disease-causing genes. Suicide gene delivery introduces genetic sequences that induce an apoptotic response in cells, usually to kill cancerous growths. In a slightly different context, virotherapy can also refer more broadly to the use of viruses to treat certain medical conditions by killing pathogens.

<span class="mw-page-title-main">History of cancer chemotherapy</span>

The era of cancer chemotherapy began in the 1940s with the first use of nitrogen mustards and folic acid antagonist drugs. The targeted therapy revolution has arrived, but many of the principles and limitations of chemotherapy discovered by the early researchers still apply.

Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.

The International Cancer Genome Consortium (ICGC) is a voluntary scientific organization that provides a forum for collaboration among the world's leading cancer and genomic researchers. The ICGC was launched in 2008 to coordinate large-scale cancer genome studies in tumours from 50 cancer types and/or subtypes that are of main importance across the globe.

<span class="mw-page-title-main">Lloyd J. Old</span> 20th-century American immunology researcher

Lloyd John Old was one of the founders and standard-bearers of the field of cancer immunology. When Old began his career in 1958, tumor immunology was in its infancy. Today, cancer immunotherapies are emerging as a significant advance in cancer therapy.

Timothy J. Ley

Timothy J. Ley is an American hematologist and cancer biologist. He is the Lewis T. and Rosalind B. Apple Professor of Oncology in the department of medicine, and is chief of the section of stem cell biology in the division of oncology at Washington University in St. Louis. He is a member of the Alvin J. Siteman Cancer Center.

Racotumomab is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by ReComBio, an international public-private consortium with the participation of the Center of Molecular Immunology at Havana, Cuba (CIM) and researchers from Buenos Aires University and National University of Quilmes in Argentina. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.

<span class="mw-page-title-main">Signs and symptoms of cancer</span> Medical condition

Cancer symptoms are changes in the body caused by the presence of cancer. They are usually caused by the effect of a cancer on the part of the body where it is growing, although the disease can cause more general symptoms such as weight loss or tiredness. There are more than 100 different types of cancer with a wide range of signs and symptoms which can manifest in different ways.

<span class="mw-page-title-main">Cancer biomarker</span> Substance or process that is indicative of the presence of cancer in the body

A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood or serum.

<span class="mw-page-title-main">Childhood cancer</span> Medical condition

Childhood cancer is cancer in a child. About 80% of childhood cancer cases in high-income countries can be successfully treated via modern medical treatments and optimal patient care. However, only about 10% of children diagnosed with cancer reside in high-income countries where the necessary treatments and care is available. Childhood cancer represents only about 1% of all types of cancers diagnosed in children and adults, It is often more complex than adult cancers with unique biological characteristics and research and treatment is yet very challenging and limited. For this reason, childhood cancer is often ignored in control planning, contributing to the burden of missed opportunities for its diagnoses and management in countries that are low- and mid-income.

University of Virginia Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center affiliated with the University of Virginia School of Medicine and the UVA Health System.

<span class="mw-page-title-main">David H. Gutmann</span> American neurologist

David Hillel Gutmann is an American neurologist-neuroscientist. He teaches at Washington University in St. Louis, where he is the Donald O. Schnuck Family Professor, and Director of the Washington University Neurofibromatosis Center. He is an international expert in Neurofibromatosis, pioneering the use of preclinical models to understand brain tumors and neurodevelopmental delays in children with NF1.

Catherine J. Wu is an American physician-scientist who studies oncology. She is a Professor of Medicine and Chief of Division of Stem Cell Transplantation and Cellular Therapies at the Dana–Farber Cancer Institute. Her research focuses on longitudinal studies of patients with chronic lymphocytic leukemia (CLL).

David Terry Curiel is an American cancer biologist. He is a professor of Radiation Oncology at Washington University School of Medicine and Director of the Biologic Therapeutics Center. In 1995, Curiel led a research team who were the first to develop a vaccine based on messenger RNA. Although they published proof of concept, he could not continue testing due to a lack of funding. In 2021, Curiel developed a vaccine that targets the SARS-CoV-2 virus through the nose.

Rebecca Aft is an American surgical oncologist and breast cancer researcher. Holds the inaugural title of Moley Professor of Endocrine and Oncologic Surgery at Washington University School of Medicine in St. Louis. Aft studies the mechanisms of breast cancer metastasis and explores potential targets for treatment. Her work has identified the anti-metastatic effects of bisphosphonates in patients with breast cancer. 

References

  1. VandeWater, Judith (4 January 2005). "St. Louis cancer center achieves highest designation". St. Louis Post-Dispatch. Retrieved 27 June 2012.
  2. "NCCN Member Institutions". National Comprehensive Cancer Network. Retrieved 27 March 2012.
  3. "Siteman joins cancer center alliance". St. Louis Business Journal. 21 March 2006. Retrieved 29 June 2012.
  4. "Siteman Cancer Center earns highest NCI rating". The Cancer Letter. 19 June 2020. Retrieved 28 July 2020.
  5. Bryant, Tim (30 July 2021). "Washington U. to open 659,000-square-foot cancer center in Central West End". St. Louis Post-Dispatch. Retrieved 30 July 2021.
  6. Rizvic, Veneta (22 October 2019). "Siteman Cancer Center unveils opening date for $26.3M facility in Florissant". St. Louis Business Journal. Retrieved 12 December 2019.
  7. Liss, Samantha (2 January 2013). "$27.5 million outpatient Siteman Cancer Center to open Monday". St. Louis Business Journal. Retrieved 11 January 2013.
  8. Maddox, Teri (13 January 2020). "Siteman Cancer Center location opening in Shiloh; Swansea office complex for sale". Belleville News-Democrat. Retrieved 16 January 2020.
  9. "Couple donate $35 million for cancer research". St. Louis Post-Dispatch. 20 November 1999. Retrieved 24 June 2013.(subscription required)
  10. "Siteman Cancer Center gets $23M". St. Louis Business Journal. 1 November 2010. Retrieved 27 March 2012.
  11. "National Comprehensive Cancer Network, MD, PhD". Siteman Cancer Center. Retrieved 29 March 2012.
  12. VandeWater, Judith (16 August 2001). "Siteman Center Here Wins Designation from National Cancer Institute". St. Louis Post-Dispatch. Retrieved 15 June 2012.
  13. VandeWater, Judith (4 January 2005). "Siteman Cancer Center here achieves highest designation". St. Louis Post-Dispatch. Retrieved 15 June 2012.
  14. Munz, Michele (21 November 2010). "Siteman Cancer Center designated as Comprehensive Cancer Center, gets $23 million". St. Louis Post-Dispatch. Retrieved 13 April 2012.
  15. "St. Louis philanthropist endows cancer fund". The Associated Press. 26 January 2010. Archived from the original on 2010-04-07. Retrieved 15 June 2012.
  16. "NCCN Member Institution Profile". National Comprehensive Cancer Network. Archived from the original on 2012-05-12. Retrieved 15 March 2012.
  17. "Patient & Visitor Information". Siteman Cancer Center. Retrieved 15 May 2012.
  18. "St. Louis Medical Organizations Plan More Proton Therapy". U.S. News & World Report. Retrieved 10 December 2018.
  19. "Find A Clinical Trial". Siteman Cancer Center. Retrieved 15 October 2017.
  20. "About Siteman". Siteman Cancer Center. Retrieved 27 October 2017.
  21. "Who and What Was Hot in Scientific Research in 2012" . Retrieved 5 June 2013.
  22. Berson, Scott (30 May 2018). "Scientists created a brain-cancer vaccine - and so far it's 'remarkably promising'". The McClatchy Company/Miami Herald. Retrieved 14 August 2018.
  23. Bernhard, Blythe (19 August 2017). "New treatment for deadly blood cancers expected to be approved soon". St. Louis Post-Dispatch. Retrieved 3 October 2017.
  24. McGinley, Laurie (18 October 2017). "Cutting-edge immunotherapy treatment approved for another deadly cancer". The Washington Post. Retrieved 25 October 2017.
  25. Roberts, Michelle (5 September 2017). "Zika virus used to treat aggressive brain cancer". St. Louis Post-Dispatch. Retrieved 3 October 2017.
  26. Gruber, Ben (4 May 2016). "Laser brain cancer treatment may bring extra advantage". Reuters. Retrieved 13 May 2016.
  27. Norton, Amy (2 April 2015). "Experimental Melanoma Vaccine Shows Early Promise". HealthDay. Retrieved 14 September 2015.
  28. "Urine Test Shows Promise for Early Diagnosis of Kidney Cancer". HealthDay. 20 March 2015. Retrieved 14 September 2015.
  29. Mahesh, Roshni (2 December 2014). "Vaccine to Slow Down Metastatic Breast Cancer". International Business Times. Retrieved 14 September 2015.
  30. Mintz, Joe (11 February 2014). "New Glasses Makes Sure 'No Cancer Is Left Behind,' Causes Malignant Cells To Glow Blue". International Business Times. Retrieved 14 September 2015.
  31. Winslow, Ron (1 May 2013). "Genomic Studies Unlock Details on Two Cancers". The Wall Street Journal. Retrieved 1 May 2013.
  32. Kolata, Gina (7 July 2012). "In Treatment for Leukemia, Glimpses of the Future". The New York Times. Retrieved 20 July 2012. "Frontiers in Cancer Research". Charlie Rose. New York. 17 July 2012. 28 minutes in. PBS. Archived from the original on 2012-07-21. Retrieved 2012-07-20.
  33. "Gene therapy: Genetic mutations predict which cancers will respond to treatment". The Economist. 16 June 2012. Retrieved 16 June 2012.
  34. "In Nurses' Lives, a Treasure Trove of Health Data". The New York Times. 15 September 1998. Retrieved 29 June 2012.
  35. Dohney, Kathleen (9 April 2011). "Teen Drinking May Boost Odds of Precancerous Breast Changes". HealthDay News and U.S. News & World Report. Retrieved 16 April 2012.
  36. Harmon, Katherine (28 March 2011). "U.S. Cancer Rates Could Be Cut in Half Today Based on What's Already Known". Scientific American. Retrieved 16 April 2012.
  37. Harmon, Katherine (March 2012). "U.S. Cancer Rates Could Be Cut in Half Today Based on What's Already Known". Scientific American. Retrieved 6 April 2012.
  38. Gamble, Molly (18 January 2012). "70 Hospitals and Health Systems With Great Oncology Programs". Becker’s Hospital Review. Retrieved 20 June 2012.
  39. Szabo, Liz (26 January 2010). "Genetic study targets cancer in kids". USA Today. Retrieved 20 June 2012.
  40. Grady, Denise (6 November 2008). "Experts Decode Cancer Patient's Genes, Seeking Treatment Clues". The New York Times. Retrieved 20 July 2012.
  41. "Nanoparticles used to track cells". UPI. 27 July 2007. Retrieved 25 July 2012.
  42. Melcer, Rachel (27 July 2007). "Innovating with Daniel Low". St. Louis Post-Dispatch. St. Louis. pp. B4.
  43. Lihong Wang, Ph.D. (30 April 2012). New technique brings cancer screening into sharper focus (Web news). St. Louis: Reuters. Retrieved 25 June 2012.ß
  44. "Breast cancer vaccine ready for tests soon". The Daily Telegraph. 10 March 2005. Archived from the original on 6 February 2012. Retrieved 15 June 2012.
  45. Hesman, Tina (15 June 2001). "Scan test may aid choice for breast cancer therapy". St. Louis Post-Dispatch. St. Louis. pp. C5.
  46. Siegel, Judy (29 April 2001). "Immune system shown to prevent and shape cancer susceptibility". The Jerusalem Post. Jerusalem. p. 4.
  47. Derbyshire, David (21 November 2007). "Living your entire life with cancer – Keeping disease dormant". The Daily Telegraph. Surry Hills, Australia. p. 25.
  48. "Cancer Care Tied to Genetic Makeup". The Toronto Star. 26 March 2001. pp. A06.
  49. "First magnet-controlled brain surgery performed". BBC News. 23 December 1998. Retrieved 13 April 2012.
  50. Signor, Roger (29 June 1994). "WU Surgeons Remove Gland, Cancer Threat". St. Louis Post-Dispatch. St. Louis, Missouri. pp. 1A.
  51. "Leukemia Victims Get Own Marrow In Transplants". The Washington Post. Washington, D.C. 24 August 1979. pp. A9.
  52. Saxon, Wolfgang (21 June 1996). "Michel M. Ter-Pogossian, 71; Led Research on PET Scanner". The New York Times. Retrieved 4 April 2012.Ter-Pogossian, M.M.; Phelps, M.E.; Hoffman, E.J.; Mullani, N.A. (January 1975). "A positron-emission transaxial tomograph for nuclear imaging (PETT)". Radiology. 114 (1). Philadelphia, Pa.: Radiological Society of North America: 89–98. doi:10.1148/114.1.89. ISSN   0033-8419. PMID   1208874.
  53. "The New Nobels". Newsweek. 27 October 1986. p. 111.
  54. Tilyou, Sarah M. (May 1989). "History of Nuclear Medicine in St. Louis: A City of Nuclear Medicine Landmarks and Innovators". The Journal of Nuclear Medicine. 30 (5). Reston, Va.: Society of Nuclear Medicine: 569–579. ISSN   0161-5505 . Retrieved 13 April 2012.
  55. Tilyou, Sarah M. (May 1989). "History of Nuclear Medicine in St. Louis: A City of Nuclear Medicine Landmarks and Innovators". The Journal of Nuclear Medicine. 30 (5). Reston, Va.: Society of Nuclear Medicine: 569–579. ISSN   0161-5505 . Retrieved 13 April 2012.
  56. "Medicine: Death of a Surgeon". Time. 18 March 1957. Archived from the original on September 30, 2007. Retrieved 6 April 2012.
  57. White, Larry C. (June 1988) [1988], Merchants of Death: The American Tobacco Industry (1 ed.), Beech Tree Books, ISBN   978-0688067069
  58. "Health Scan: Scientists learn how colon cancer spreads". The Jerusalem Post. 23 September 2007. Retrieved 15 June 2012.
  59. "Zuum – Health Tracker". iTunes . Retrieved 26 June 2012.
  60. "TOGETHER - Every Woman's Guide to Preventing Breast Cancer". iTunes . Retrieved 14 September 2015.
  61. Wittenauer, Cheryl (24 September 2008). "Mo. Blacks closing racial gap in new cancer cases". The Associated Press. St. Louis. Retrieved 26 June 2012.
  62. Jackson Jr., Harry (23 August 2004). "Black St. Louisans get healthy at church". St. Louis Post-Dispatch. Retrieved 24 June 2013.(subscription required)
  63. Sheridan, Kerry (28 March 2012). "Half of all cancers are preventable: study". Agence France Presse. Washington, D.C. Archived from the original on January 25, 2013. Retrieved 26 June 2012.
  64. Gregorian, Cynthia Billhartz (27 October 2010). "Researchers target cancer screenings among blacks". St. Louis Post-Dispatch. Retrieved 20 July 2012.
  65. Jackson Jr., Harry (23 August 2004). "Black St. Louisans get healthy at church". St. Louis Post-Dispatch. Retrieved 24 June 2013.(subscription required)
  66. Kreuter, Matthew W.; Alcaraz, Kassandra I.; Pfeiffer, Debra; Christopher, Kara (March–April 2008). "Using Dissemination Research to Identify Optimal Community Settings for Tailored Breast Cancer Information Kiosks". Journal of Public Health Management and Practice. 14 (2). Lippincott Williams & Wilkins, Inc.: 160–169. doi:10.1097/01.PHH.0000311895.57831.02. PMID   18287923.
  67. "Charity Race Raised More Than $500,000 to Fight Breast Cancer". St. Louis Post-Dispatch. 28 October 2000. Retrieved 24 June 2013.
  68. "Mammography Van". Siteman Cancer Center. Retrieved 6 April 2012.
  69. Jackson Jr., Jodie (4 March 2017). "Stewart Cancer Center joins new Siteman network". Columbia Daily Tribune. Retrieved 14 August 2018.
  70. Amos, Lori (26 June 2018). "PCRMC advancing treatment in the community". Rolla Daily News. Retrieved 14 August 2018.
  71. Robbins, Brian (2 May 2019). "Siteman continues push into Illinois as Alton hospital joins cancer-treatment network". St. Louis Business Journal. Retrieved 17 May 2019.
  72. Halstead, Marilyn (9 December 2020). "Southern Illinois Healthcare is now a Siteman Cancer Network affiliate". The Southern Illinoisan. Retrieved 30 July 2021.